Alzinova AB
Alzinova AB is a clinical-stage biopharma company focused on developing treatments for Alzheimer's disease by targeting neurotoxic amyloid beta oligomers using its proprietary ACC peptide technology. The lead candidate, ALZ-101, is a therapeutic vaccine designed to modify the disease's progression, addressing the significant global health challenge posed by the approximately 40 million individuals affected by Alzheimer's.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$52.7KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Alzinova AB is a clinical-stage biopharma company focused on developing treatments for Alzheimer's disease by targeting neurotoxic amyloid beta oligomers using its proprietary ACC peptide technology. The lead candidate, ALZ-101, is a therapeutic vaccine designed to modify the disease's progression, addressing the significant global health challenge posed by the approximately 40 million individuals affected by Alzheimer's.